Research method
Gene Knockout and Knockdown
16 studies
Gene knockout and knockdown remove or reduce a gene product — by deletion, RNAi/shRNA, or receptor-null alleles — and then score a phenotype. The output is a loss-of-function contrast: growth, trafficking, signalling, or metabolite change relative to a matched control. A knockdown that phenocopies a drug is still not a clinical trial, and not every paper tagged for this method actually deletes a gene.
Cell and developmental biologists use KO/KD when they need causal evidence that a named protein is required for a trafficking or signalling step. It answers 'what fails when this gene is gone or reduced?' The main limitation is off-target RNAi, incomplete knockdown, and the fact that proximity maps or single-cell catalogues can be lexicon-tagged as knockdown papers without ever perturbing the gene.
Studies
16
Findings
5
7 supporting · 0 challenging · 0 qualifying citations
Open tensions
2
Currently
What we know
- CSNK1E/CK1ε was a cancer-preferential dependency: shRNA and kinase inhibitors phenocopied each other, and growth arrest was PERIOD2-dependent in isogenic cancer versus normal models. That is a selective-dependency result, not a patient trial of CK1ε drugs.
- An RNAi screen of Drosophila deubiquitinases in wings and S2 cells found that USP8 prevents Smoothened ubiquitination, enhances Hedgehog signalling, and is required for Hh-induced surface accumulation of Smo, keeping it out of Rab5 early endosomes. The opposing ubiquitin ligase is not fully identified in every tissue.
- Interferon receptor knockouts plus statin/siRNA perturbations tied antiviral defense to sterol-pathway shutdown. Infection and type I/II IFN reduced sterol-pathway transcripts and metabolites via IFNAR1/Tyk2 and lowered SREBP2; antiviral effects of pathway blockade depended on mevalonate/geranylgeraniol, not cholesterol rescue. This is murine CMV/macrophage mechanism work, not a human statin antiviral trial.
- In Arabidopsis, combined PDLP knockouts increased GFP cell-to-cell movement, while GFP-tagged PDLP1 family proteins targeted plasmodesmata (PDLP1a: cytoplasmic C-tail, apoplastic DUF26). The KO phenotype is trafficking of a reporter, not a full catalogue of every plasmodesmal cargo.
- Three papers in this method list barely use knockout or knockdown. APEX2 proximity labelling mapped 22 outer-mitochondrial and 72 ER-membrane proteins facing the cytosol; scRNA-seq of H1 hESC progenitors found that 1.5% O2 increases CXCR4+ definitive-endoderm-like cells; caveolar-coat work purified caveolin–cavin complexes. Those are maps and culture conditions, not gene deletions.
Largest unresolved question
Loss-of-function tools are not interchangeable. CK1ε used shRNA plus inhibitors in mammalian cancer models; USP8 used Drosophila RNAi; IFN work used receptor knockouts and siRNA in macrophages; PDLP used plant combined KOs. A 'knockdown paper' in flies is not the same genetic lesion as a mouse IFNAR1 knockout or an Arabidopsis double mutant.
Procedure
How it works
The main stages of the method. Specific protocols and analysis choices vary between studies.
Choose a loss-of-function tool
Deletion, RNAi/shRNA, CRISPR, or a receptor-null allele is picked for the organism. The tools are not interchangeable: fly RNAi is not a mouse receptor knockout or a plant combined mutant.
Reduce or remove the gene product
The reagent is delivered so the transcript or protein falls. Incomplete knockdown and off-target RNAi can still produce a clean-looking phenotype of the wrong gene.
Confirm the perturbation
A blot, qPCR, or genetic rescue is used to show the intended target is down. Without that check, a screen hit is only a correlated failure.
Score a phenotype against a matched control
Growth, trafficking, signalling, or a metabolite is compared with a matched control. A knockdown that phenocopies a drug is still a cell, fly, or plant result, not a clinical trial.
Treat the contrast as a requirement test, not a catalogue
Knockout and knockdown answer what fails when this gene is gone or reduced. Proximity maps and single-cell catalogues that merely list the gene have not perturbed it and are not knockdown evidence.
Common misconceptions
If an shRNA and a kinase inhibitor give the same growth arrest, the compound is ready for patients.
CK1ε inhibitors phenocopied CSNK1E shRNA in a PERIOD2-dependent, cancer-selective model. Selectivity and potency still need medicinal chemistry; the paper is not a clinical trial.
Blocking the sterol pathway is antiviral because cells run out of cholesterol.
IFNAR1/Tyk2 signalling lowered SREBP2 and sterol-pathway metabolites, but antiviral effects of pathway blockade depended on mevalonate/geranylgeraniol, not cholesterol rescue.
APEX2 'knocked out' mitochondrial and ER surface proteins by labelling them.
APEX2 is proximity biotinylation in living cells. The 22 OMM and 72 ERM enrichments are an inventory, not functional validation or deletion of each newly mapped protein.
Related
Claim ledger
What the evidence shows
Drawn from 16 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
CSNK1E/CK1ε was a cancer-preferential dependency: shRNA and kinase inhibitors phenocopied each other, and growth arrest was PERIOD2-dependent in isogenic cancer versus normal models. That is a selective-dependency result, not a patient trial of CK1ε drugs.
An RNAi screen of Drosophila deubiquitinases in wings and S2 cells found that USP8 prevents Smoothened ubiquitination, enhances Hedgehog signalling, and is required for Hh-induced surface accumulation of Smo, keeping it out of Rab5 early endosomes. The opposing ubiquitin ligase is not fully identified in every tissue.
Interferon receptor knockouts plus statin/siRNA perturbations tied antiviral defense to sterol-pathway shutdown. Infection and type I/II IFN reduced sterol-pathway transcripts and metabolites via IFNAR1/Tyk2 and lowered SREBP2; antiviral effects of pathway blockade depended on mevalonate/geranylgeraniol, not cholesterol rescue. This is murine CMV/macrophage mechanism work, not a human statin antiviral trial.
In Arabidopsis, combined PDLP knockouts increased GFP cell-to-cell movement, while GFP-tagged PDLP1 family proteins targeted plasmodesmata (PDLP1a: cytoplasmic C-tail, apoplastic DUF26). The KO phenotype is trafficking of a reporter, not a full catalogue of every plasmodesmal cargo.
Three papers in this method list barely use knockout or knockdown. APEX2 proximity labelling mapped 22 outer-mitochondrial and 72 ER-membrane proteins facing the cytosol; scRNA-seq of H1 hESC progenitors found that 1.5% O2 increases CXCR4+ definitive-endoderm-like cells; caveolar-coat work purified caveolin–cavin complexes. Those are maps and culture conditions, not gene deletions.
- Mapping the faces of mitochondria and ER
- What marks definitive endoderm progenitors in hESCs?
- What proteins build the caveolar coat?
Study Role Design N Population Outcome Mapping the faces of mitochondria and ER Supports Animal / in-vitroAPEX2 proximity labeling of cytosol-facing OMM and ER membranes in living HEK 293T cells SILAC proteomic maps with two replicates per membrane — cell-resource study HEK 293T cells expressing OMM/ERM APEX2 fusions Proteomes of cytosol-facing outer mitochondrial and ER membranes What marks definitive endoderm progenitors in hESCs? Supports Animal / in-vitroscRNA-seq of H1/H9 progenitors and oxygen-condition tests during definitive endoderm differentiation N=1018 · 1,018 single cells analysed (including H1 n=212, H9 n=162, HFFs n=159) Human embryonic stem cells and lineage-specific progenitors Single-cell regulators and hypoxia effects on definitive endoderm differentiation What proteins build the caveolar coat? Supports Animal / in-vitroBiochemical purification and ultrastructure of caveolar coat proteins Structural/biochemical coat stoichiometry study — no single sample N Caveolar coat complexes (caveolins/cavins) Molecular composition and ultrastructure of the caveolar coat
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
Loss-of-function tools are not interchangeable. CK1ε used shRNA plus inhibitors in mammalian cancer models; USP8 used Drosophila RNAi; IFN work used receptor knockouts and siRNA in macrophages; PDLP used plant combined KOs. A 'knockdown paper' in flies is not the same genetic lesion as a mouse IFNAR1 knockout or an Arabidopsis double mutant.
Loss-of-function tools are not interchangeable. CK1ε used shRNA plus inhibitors in mammalian cancer models; USP8 used Drosophila RNAi; IFN work used receptor knockouts and siRNA in macrophages; PDLP used plant combined KOs. A 'knockdown paper' in flies is not the same genetic lesion as a mouse IFNAR1 knockout or an Arabidopsis double mutant.
- CK1ε, PERIOD2, and cancer-selective growth arrest
- How does USP8 turn on Smoothened?
- How interferon throttles sterol synthesis in antiviral defense
- How do proteins find plasmodesmata?
Study Role Design N Population Outcome CK1ε, PERIOD2, and cancer-selective growth arrest Supports Animal / in-vitroKinase shRNA library screen and CK1ε inhibitor assays in isogenic cancer vs normal cells Library targets 1,006 genes; cell-line dependency study — no single sample N Isogenic cancer and normal cell models Cancer-selective, PERIOD2-dependent growth arrest after CSNK1E/CK1ε inhibition How does USP8 turn on Smoothened? Supports Animal / in-vitroRNAi screen of Drosophila DUBs in wings and S2 cells focused on USP8–Smo regulation Drosophila genetics and S2 cell assays — no single sample N Drosophila tissues and S2 cells USP8 prevention of Smoothened ubiquitination promoting Hedgehog signaling How interferon throttles sterol synthesis in antiviral defense Supports Animal / in-vitroMacrophage time-series, lipidomics, IFN receptor knockouts, and murine CMV infection models Multi-assay mouse/cell study — no single primary analytic N in stored text Primary bone-marrow–derived macrophages and mice (including IFNAR1/Tyk2 models) Interferon-mediated sterol-pathway down-regulation in antiviral defense How do proteins find plasmodesmata? Supports Animal / in-vitroGFP localization and topology/knockout assays of PDLP plasmodesmal proteins Plant cell-biology localization and trafficking assays — no single sample N Arabidopsis and other plants expressing PDLP family proteins Plasmodesmal targeting of PDLPs and effects on cell-to-cell GFP movement
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Lexicon hits also disagree with the genuine KO/KD set. APEX2 inventories, hESC scRNA-seq under hypoxia, and caveolar stoichiometry do not perturb named genes, so they cannot be cited as knockdown evidence for trafficking proteins they merely list.
Lexicon hits also disagree with the genuine KO/KD set. APEX2 inventories, hESC scRNA-seq under hypoxia, and caveolar stoichiometry do not perturb named genes, so they cannot be cited as knockdown evidence for trafficking proteins they merely list.
- Mapping the faces of mitochondria and ER
- What marks definitive endoderm progenitors in hESCs?
- What proteins build the caveolar coat?
Study Role Design N Population Outcome Mapping the faces of mitochondria and ER Supports Animal / in-vitroAPEX2 proximity labeling of cytosol-facing OMM and ER membranes in living HEK 293T cells SILAC proteomic maps with two replicates per membrane — cell-resource study HEK 293T cells expressing OMM/ERM APEX2 fusions Proteomes of cytosol-facing outer mitochondrial and ER membranes What marks definitive endoderm progenitors in hESCs? Supports Animal / in-vitroscRNA-seq of H1/H9 progenitors and oxygen-condition tests during definitive endoderm differentiation N=1018 · 1,018 single cells analysed (including H1 n=212, H9 n=162, HFFs n=159) Human embryonic stem cells and lineage-specific progenitors Single-cell regulators and hypoxia effects on definitive endoderm differentiation What proteins build the caveolar coat? Supports Animal / in-vitroBiochemical purification and ultrastructure of caveolar coat proteins Structural/biochemical coat stoichiometry study — no single sample N Caveolar coat complexes (caveolins/cavins) Molecular composition and ultrastructure of the caveolar coat
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Gene Knockout and Knockdown
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
- Coverage updated · Concept page published
Papers
16 studies in this library bear on Gene Knockout and Knockdown, ordered by citations.
- What marks definitive endoderm progenitors in hESCs?
Single-cell RNA-seq separates definitive endoderm progenitors and links metabolism/hypoxia to DE differentiation.
- FLI1 circRNA FECR1 drives metastasis
Exonic circular RNA FECR1 binds the FLI1 promoter and epigenetically activates FLI1 in breast cancer.
- Mapping the faces of mitochondria and ER
APEX2 proximity biotinylation yields high-quality proteomic maps of cytosol-facing outer mitochondrial and ER membranes in living human cells.
- How do proteins find plasmodesmata?
PDLP1 is a type I membrane protein targeted to plasmodesmata; altering PDLP dosage changes GFP cell-to-cell trafficking.
- Selective bacterial BSH shifts host metabolism
Bacteroides bile salt hydrolase BT2086 selectively deconjugates bile acids and alters host metabolism.
- How interferon throttles sterol synthesis in antiviral defense
Type I interferon couples viral sensing to down-regulation of the sterol pathway’s mevalonate–isoprenoid arm, limiting viral growth.
- LOX1 oxylipins close stomata in defense
Guard-cell LOX1 drives ABA-independent stomatal closure that limits Pseudomonas colonization.
- How do E. coli vesicles talk to gut epithelium?
Outer membrane vesicles from probiotic and commensal E. coli deliver ligands that activate NOD1-mediated immune responses in intestinal epithelial cells.
Show 8 more studiesShow fewer studies
- What proteins build the caveolar coat?
Caveolins and cavins purify as a caveolar coat complex with Cavin 1 as a core trimeric component.
- How does USP8 turn on Smoothened?
USP8 deubiquitinates Smoothened, promoting Hh-dependent cell-surface accumulation and signaling while limiting early-endosome localization.
- Histone acylations respond to plant stress
Rice histone butyrylation and crotonylation mark active chromatin and shift under starvation/submergence.
- Tiling arrays reveal plant circadian RNAs
Genome tiling arrays uncover extensive circadian-regulated transcription across the Arabidopsis genome.
- CK1ε, PERIOD2, and cancer-selective growth arrest
Cancer cells depend more than normal cells on casein kinase 1-epsilon; inhibiting CK1ε causes PERIOD2-dependent growth arrest.
- How MC4R variants scramble receptor trafficking
Obesity-linked MC4R mutations disrupt plasma-membrane localization, endocytosis and β-arrestin pathways beyond classical cAMP loss-of-function.
- How does ZFP36 reshape metabolism after growth signals?
Growth factors induce ZFP36, which binds and decays metabolic enzyme/transporter mRNAs—especially Eno2—tuning glycolytic metabolism.
- Folliculin tunes mTORC1 toward TFE3
FLCN–RagC signaling makes mTORC1 substrate-selective for TFE3 phosphorylation under amino-acid cues.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
Loss-of-function tools are not interchangeable. CK1ε used shRNA plus inhibitors in mammalian cancer models; USP8 used Drosophila RNAi; IFN work used receptor knockouts and siRNA in macrophages; PDLP used plant combined KOs. A 'knockdown paper' in flies is not the same genetic lesion as a mouse IFNAR1 knockout or an Arabidopsis double mutant.
Lexicon hits also disagree with the genuine KO/KD set. APEX2 inventories, hESC scRNA-seq under hypoxia, and caveolar stoichiometry do not perturb named genes, so they cannot be cited as knockdown evidence for trafficking proteins they merely list.
Ask PaperFren about Gene Knockout and Knockdown
Study this conceptflashcards and short-answer questions
CK1ε inhibitors phenocopy CSNK1E shRNA and arrest depends on PERIOD2. What two controls make that a dependency claim rather than a generic toxin?
Isogenic cancer versus normal models show cancer-preferential arrest, and PERIOD2 dependence ties the phenotype to the circadian substrate rather than unspecific kinase shutdown. It is still not a patient trial.
USP8 RNAi keeps Smoothened off Rab5 early endosomes and on the cell surface under Hedgehog. What trafficking claim is licensed, and what ligase question remains?
USP8 is required for Hh-induced surface accumulation by limiting Smo ubiquitination. The ubiquitin ligase that opposes USP8 on Smo is not fully identified in every tissue.
Why does cholesterol add-back failing to rescue IFN-driven antiviral effects change the interpretation of 'sterol-pathway knockdown'?
If cholesterol rescue does not restore defense while mevalonate/geranylgeraniol matter, the relevant branch is isoprenoid signalling, not bulk cholesterol. IFNAR1/Tyk2 and SREBP2 still explain the transcriptional drop.
Combined PDLP knockouts increase GFP movement through plasmodesmata. Why is that not a complete list of plasmodesmal cargoes?
The phenotype is increased movement of a GFP reporter when PDLPs are gone. The paper localises PDLP1 family proteins and maps PDLP1a topology but does not catalogue every cargo regulated by PDLPs.